10th Liquid Biopsy for Precision Oncology Summit | February 3-5, 2026 | Free* for Biopharma

Conference Details:

10th Liquid Biopsy for Precision Oncology Summit | February 3-5, 2026 | Free* for Biopharma

Conference Description:

The 10th Liquid Biopsy for Precision Oncology Summit is the leading annual meeting for pharma, biotech, diagnostics, consortia, academia and patient voices to accelerate collaboration and progress in the rapidly advancing field of liquid biopsy.

Now in its 10th year, this meeting delivers unparalleled insights, data, technology updates, and strategies spanning the entire drug development pipeline – from preclinical discovery, through clinical translation, to regulatory approval, reimbursement, and commercial adoption.

If you are working in precision oncology, or need enhanced insights into your patient population, optimized diagnostic and prognostic tools, or earlier detection of disease, this meeting should be considered a staple entry in your conference calendar. Across ctDNA, MRD, multi-omic biomarkers, and novel analytes, you will see how pharma are strategically integrating liquid biopsies into therapeutic pipelines, how diagnostic companies are designing more sensitive assays, and how the field is overcoming barriers to widespread clinical adoption.

What’s more?
Tickets are complimentary* for biopharma.

Tickets: https://go.evvnt.com/3292097-2?pid=154
Prices:
Conference Only – Vendor Pricing: USD 3999.00,
Conference only – Drug Developer and Academic: USD 0.50

Speakers: Oliver Rosen, Chief Medical Officer, Akamis Bio, Leandro Grimaldi, Senior Director, Head of Strategy and Operations, Precision, Amgen, Amrita Pati, Executive Director of Computational Biology, Precision Medicine, Amgen, Cedric Dos Santos, Global Product Leader, AstraZeneca, Hua Gong, Vice President – Translational Medicine, BBOT (BridgeBio Oncology Therapeutics), Lauren Leiman, Executive Director, BLOODPAC, Joan Chen, Executive Director – Bioinformatics, Boundless Bio, Jon Baden, Executive Director, Head of Precision Medicine At Bristol Myers Squibb, Bristol Myers Squibb, Cynthia Sandoval, PhD Senior Director, Clinical Biomarker Development, Eli Lilly, Michelle Neff, Associate Vice President – Global Regulatory Affairs, Diagnostics and Companion Diagnostics, Eli Lilly, Hadly Clark, Director FasterCures, Milken Institute, Daad Abighanem, Cancer Patient/Survivor, Fight CRC, Anjee Davis, Chief Executive Officer, FightCRC, Yanwen Jiang, Distinguished Scientist, Genentech, Ildiko Csiki, Chief Medical Officer, Geneos Therapeutics, Claudia Dollins, Vice President, Regulatory Affairs, GSK, Fernando Cruz-Guilloty, Director – Oncology Precision Medicine and Lung Franchise Lead, Johnson and Johnson, David Weingeist, Scientific Director, Oncology Precision Medicine and Diagnostics, Johnson and Johnson, Partha Das, Global Medical Director – Precision Medicine, Johnson and Johnson, Anthony Chi, Medical Director, Kaiser Kermanente, Anneleen Daemen, Executive Director – Translational Medicine, ORIC Pharmaceuticals, Steffan Ho, Vice President, Head of Translational Oncology, Pfizer, Jennifer Hamilton, Vice President and Head of Precision Medicine, Regeneron, Zoe June Assaf, Senior Director, Cancer Genomics and Emerging Technologies, Revolution Medicines, Amer Mirza, Vice President, Disease Biology and Translational Sciences, Septerna, Hatim Hassan, Professor of Medical Oncology, UC San Diego, Daniel Kim, Assistant Professor and Co-Chair, UC Santa Cruz and NIH Liquid Biopsy Scientific Interest Group, Jelveh Lameh, Head, Translational Research, Zai Lab

Time: 08:00 to 18:00

Important Dates:

• Conference start date: February 03, 2026
• Conference end date: February 05, 2026

Conference Information:

• Category: Health and Medicine
• Location: United States
• Website: http://go.evvnt.com/3292097-1?pid=154

Contact Information:

• Address: San Diego Marriott La Jolla, 4240 La Jolla Village Drive, La Jolla, California, 92037, United States